Press Releases

Press Releases

Date Title
December 10, 2018
Role to focus on business development as Genocea expands its immunotherapy pipeline and explores additional applications of its ATLAS™ neoantigen identification platform CAMBRIDGE, Mass. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company
November 15, 2018
Event to be webcast live at 12 pm ET CAMBRIDGE, Mass. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, announced today that it will host a Key Opinion Leader (KOL) event focused on the latest
November 6, 2018
ATLAS™-identified “inhibitory” neoantigens promote tumor growth in mouse model  ATLAS platform continues to differentiate versus in silico methods for true  neoantigen identification CAMBRIDGE, Mass. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.
November 1, 2018
Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial enrolling patients Presenting novel findings at upcoming SITC conference Conference call today at 9:00 am ET CAMBRIDGE, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical company
October 25, 2018
CAMBRIDGE, Mass. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.  (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, November 1, 2018 at 9:00 a.m.
October 9, 2018
Posters showcase ability of ATLAS™ platform to identify neoantigens for inclusion in and exclusion from personalized immunotherapies CAMBRIDGE, Mass. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer
October 1, 2018
CAMBRIDGE, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced two additions to its leadership team: Thomas Davis , M.D. as Chief Medical Officer and Derek Meisner , J.D.
September 24, 2018
CAMBRIDGE, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at two upcoming investor
August 29, 2018

CAMBRIDGE, Mass. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at two upcoming investor

August 2, 2018

Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial underway ATLAS™ platform continues to stand apart from in silico methods of neoantigen identification Conference call today at 9:00 am ET CAMBRIDGE, Mass. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.

July 26, 2018

CAMBRIDGE, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, August 2, 2018 at 9:00 a.m.

June 1, 2018

Presentation to be webcast live at 12:30 pm ET on June 8, 2018 CAMBRIDGE, Mass. , June 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark , president and chief executive officer,

May 10, 2018
- Company files IND for lead neoantigen vaccine program, GEN-009 -  - ATLAS ™ platform continues to stand apart from in silico methods of neoantigen identification -  - Conference call today at 9 am ET - CAMBRIDGE, Mass. , May 10, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.
May 4, 2018
CAMBRIDGE, Mass. , May 04, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. ( NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, May 10, 2018 at 9:00 a.m.
April 30, 2018
- C ompany plans to initiate Phase 1/2a clinical program later this year -  - Top-line immune response data expected in the first half of 2019 - CAMBRIDGE, Mass. , April 30, 2018 (GLOBE NEWSWIRE) --   Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer
April 18, 2018
- ATLAS data demonstrate in silico methods miss most empirically confirmed neoantigens - - ATLAS able to identify inhibitory neoantigens - - Mouse ATLAS melanoma model developed to study mechanism of inhibitory antigens - CAMBRIDGE, Mass. , April 18, 2018 (GLOBE NEWSWIRE) --   Genocea Biosciences,
April 9, 2018
CAMBRIDGE, Mass. , April 09, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced upcoming presentations at the 2018 Annual Meeting of the American Association for Cancer Research ( AACR 2018 ), taking
March 12, 2018
CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced the appointment of Narinder Singh as senior vice president of pharmaceutical sciences and manufacturing. Mr.
March 5, 2018
CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at two upcoming investor
February 15, 2018
- GEN-009 neoantigen vaccine advancing to IND filing - - Balance sheet strengthened with $55m gross proceeds from January equity financing - - Conference call today at 9 am ET - CAMBRIDGE, Mass. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.
February 12, 2018
Follows NEA investment in Genocea during January 2018 concurrent equity financings
February 8, 2018
CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, February 15, 2018 at 9:00 a.m.
January 17, 2018
New Enterprise Associates ("NEA") and Vivo Capital significant investors in financing Genocea intends to elect an NEA representative to Genocea board of directors CAMBRIDGE, Mass. , Jan. 17, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company that discovers
January 16, 2018
CAMBRIDGE, Mass. , Jan. 16, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company that discovers and develops novel cancer vaccines, announced today that it intends to offer and sell in concurrent underwritten public offerings (i) shares of its common stock